Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy?

argenx SE (NASDAQ:ARGX) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple seronegative patients.

On May 7, argenx SE (NASDAQ:ARGX) reported first-quarter 2026 financials, posting $1.3 billion in global product net sales, up 63% year over year, while flagging a May 10, 2026, PDUFA date for seronegative gMG. CEO Karen Massey said argenx “continues to deliver meaningful impact,” citing a 17th consecutive quarter of VYVGART growth and pointing to expansion across MG populations.

Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy?

disease-4392163_1920

Argenx said it expects myositis topline data in the third quarter and MMN readouts in the fourth quarter of 2026 while advancing FcRn programs, including Phase 3-ready ARGX-213. Management added that it aims to treat 50,000 patients globally and secure 10 labeled signs by 2030, the company said.

argenx SE (NASDAQ:ARGX) is a global immunology company that works to improve the lives of people suffering from severe autoimmune diseases. It is operated in the United States, Japan, EMEA, and China.

While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.